Other analysts also recently issued reports about the company. UBS Group reiterated a buy rating and set a $148.00 price target on shares of Johnson & Johnson in a report on Saturday, September 30th. Jefferies Group increased their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a buy rating in a report on Monday, October 16th. Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a buy rating in a report on Friday, October 6th. Citigroup increased their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a buy rating in a report on Monday, October 23rd. Finally, Barclays increased their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an equal weight rating in a research report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $145.52.
Shares of Johnson & Johnson (NYSE JNJ) traded up $0.82 during trading on Monday, reaching $144.79. The company’s stock had a trading volume of 4,962,045 shares, compared to its average volume of 5,920,000. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $145.68. The firm has a market cap of $388,980.00, a P/E ratio of 25.14, a P/E/G ratio of 2.67 and a beta of 0.80.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.32%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
Several hedge funds have recently added to or reduced their stakes in the company. Acropolis Investment Management LLC lifted its position in Johnson & Johnson by 26.3% in the 4th quarter. Acropolis Investment Management LLC now owns 24,383 shares of the company’s stock valued at $3,407,000 after acquiring an additional 5,080 shares in the last quarter. Sawyer & Company Inc bought a new position in Johnson & Johnson in the 4th quarter valued at about $3,726,000. American National Bank lifted its position in Johnson & Johnson by 6.0% in the 4th quarter. American National Bank now owns 58,898 shares of the company’s stock valued at $8,230,000 after acquiring an additional 3,309 shares in the last quarter. Stock Yards Bank & Trust Co. lifted its position in Johnson & Johnson by 13.7% in the 4th quarter. Stock Yards Bank & Trust Co. now owns 153,470 shares of the company’s stock valued at $21,442,000 after acquiring an additional 18,540 shares in the last quarter. Finally, Windward Capital Management Co. CA lifted its position in Johnson & Johnson by 3.0% in the 4th quarter. Windward Capital Management Co. CA now owns 93,768 shares of the company’s stock valued at $13,101,000 after acquiring an additional 2,755 shares in the last quarter. 65.70% of the stock is currently owned by institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.